Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
506.00    1.00 (0.20%)
Bid:
505.50
Ask:
506.50
Spread: 1.00 (0.198%)
Market Cap: £2.24b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Acquisition

31 Mar 2022 07:00

RNS Number : 6742G
Tate & Lyle PLC
31 March 2022
 

 

THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018

 

FOR IMMEDIATE RELEASE

 

Tate & Lyle PLC

 

Tate & Lyle to acquire leading dietary fibre business in China

 

London, UK, 31 March 2022 - Tate & Lyle PLC (Tate & Lyle), a leading global provider of food and beverage ingredients and solutions, announces that it has signed an agreement to acquire Quantum Hi-Tech (Guangdong) Biological Co., Ltd (Quantum), a leading prebiotic dietary fibre business in China from ChemPartner Pharmatech Co., Ltd (ChemPartner) for a total consideration of US$237 million.

 

Key highlights:

· Fully aligned to strategy to become growth-focused food and beverage solutions business

· Strengthens position as a leading global player in fast-growing global dietary fibres market

· Adds new, speciality and complementary products to portfolio

· Brings strong R&D expertise with proprietary manufacturing processes and technologies

· Strengthens fortification platform and enhances integrated solutions capabilities

· Significantly extends presence and customer offering in China and Asia

· Expected to be accretive to revenue growth and EBITDA margin in first year of ownership 

· Completion expected in the second quarter of 2022 calendar year.

 

Quantum engages in the research, development, production and sale of fructo-oligosaccharides (FOS) and galacto-oligosaccharides (GOS). Together, FOS (from sucrose) and GOS (from milk sugar/lactose) represent around 25%2 of the global dietary fibres market which is forecast to grow at around 6% per annum3. In China, which currently represents the majority of Quantum's sales, the FOS and GOS market is forecast to grow at around 10% per annum3.

 

The acquisition of Quantum significantly strengthens Tate & Lyle's position as a leading global player in dietary fibres, bringing a high-quality portfolio of speciality fibres, strong R&D capabilities and proprietary manufacturing processes and technologies. The acquisition expands Tate & Lyle's ability to provide added-fibre solutions for its customers across a range of categories including dairy, beverages, bakery and nutrition (including infant nutrition), and to meet growing consumer interest in gut health. It also significantly expands Tate & Lyle's presence in China and Asia, and extends its capabilities to create solutions across food and drink utilising its leading speciality ingredient portfolio.

 

The transaction is subject to approval by the shareholders of ChemPartner, a public company listed in China, of which Quantum is a wholly-owned subsidiary. At completion, consideration4 will be paid in cash for 100% of the equity interests in Quantum. For the 11 months ended 30 November 2021, Quantum generated revenue of US$46 million and EBITDA of US$14 million5. The acquisition is expected to be accretive to revenue growth and EBITDA margin for Tate & Lyle in the first year of ownership. 

 

Quantum produces its range of FOS and GOS fibres at its production site in Guangdong Province, Southern China. The management team of Quantum will join Tate & Lyle at completion. Closing of the transaction is expected to occur in the second quarter of calendar year 2022.

 

Nick Hampton, Chief Executive at Tate & Lyle, said:

"We are delighted to announce the agreement to acquire Quantum, a leader in prebiotic dietary fibres and a business recognised for its high-quality ingredients and solutions. This acquisition significantly strengthens our fortification capabilities and expands our customer offering in key food and drink categories. FOS and GOS are highly complementary to our existing fibre portfolio and will enable us to offer a broader range of solutions to our customers. The acquisition is also very much in line with our purpose to support healthy living by improving gut health, and driving sugar and calorie reduction and fibre fortification for consumers across the world."

 

Mr. Zeng Xianwei, Chairman of the Board of ChemPartner, said:

"We are proud of the Quantum business we have built over the last 20 years, providing high-quality products to support healthier living for people across China and beyond. Tate & Lyle, with its global customer reach, strong focus on R&D, and strong fibre portfolio, is the ideal company to take Quantum on the next stage of its development. I wish them and the management team at Quantum success in the future."

 

 

ENDS

 

For more information contact Tate & Lyle PLC:

 

Investor Relations:

Christopher Marsh, VP, Investor Relations

Mobile: +44 (0) 7796 192 688

 

Media:

Nick Hasell, FTI Consulting Mobile: +44 (0) 7825 523 383

 

Notes to Editors

 

1. Tate & Lyle already offers a broad selection of soluble fibre solutions, such as its PROMITOR® Soluble Fibre and STALITE® Polydextrose, with distinctive benefits for many food and beverage categories. These enable sugar and calorie reduction as well as fibre fortification, helping to support healthier lifestyles and provide nutritional benefits, while maintaining great taste.

2. Company analysis from sources including Maia Research Global Short Chain Fructo-oligosaccharides Market Research Report 2021

3.   Volume growth (2021 - 2026); Company analysis including Maia Research Global Short Chain Fructo-oligosaccharides Market Research Report 2021

4. Consideration is on a cash-free, debt-free basis, and subject to customary working capital adjustments

5. Depreciation and amortisation charges together for the 11 months ended 30 November 2021 were US$2 million

6. As at 30 November 2021, the gross assets of Quantum were US$41 million.

7. On a pro forma 12 months basis, calculated by extrapolating the financial information for the 11 months to 30 November 2021, Quantum has annual revenue of US$50 million and EBITDA of US$15 million.

 

 

About Tate & Lyle

Tate & Lyle PLC is a leading global provider of food and beverage ingredients and solutions. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

 

Through our expertise in sweetening, mouthfeel and fibre fortification, our Food & Beverage Solutions business develops solutions which reduce sugar, calories and fat, add fibre, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings. Our Primary Products business produces nutritive sweeteners, industrial starches used in paper and packaging, acidulants and products used for animal nutrition.

 

We have around 4,200 employees working in more than 60 locations across 30 countries. Tate & Lyle's purpose is Improving Lives for Generations and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2021, Tate & Lyle sales totalled £2.8 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on Twitter, Linkedin or Facebook.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQBIGDXGGXDGDG
Date   Source Headline
4th May 20207:00 amRNSTrading Update
1st May 20203:27 pmRNSTotal Voting Rights
3rd Apr 202011:00 amRNSDirector Declaration
1st Apr 202012:26 pmRNSTotal Voting Rights
6th Feb 20207:00 amRNSTrading Statement
30th Jan 202011:45 amRNSDirector/PDMR Shareholding
7th Jan 20202:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202012:41 pmRNSBlock listing Interim Review
19th Dec 20192:00 pmRNSDirector/PDMR Shareholding
7th Nov 20197:00 amRNSHalf-year Report
3rd Oct 20193:06 pmRNSHolding(s) in Company
1st Oct 201910:14 amRNSTotal Voting Rights
19th Sep 20197:00 amRNSFULL PENSION SCHEME BUY-IN WITH LEGAL & GENERAL
6th Sep 201910:15 amRNSDirector/PDMR Shareholding
30th Aug 201912:00 pmRNSDirector Declaration
21st Aug 201910:00 amRNSDirector/PDMR Shareholding
5th Aug 20193:00 pmRNSIssue of Debt
1st Aug 20192:00 pmRNSTotal Voting Rights
25th Jul 201912:58 pmRNSResult of AGM
18th Jul 20193:00 pmRNSDirector/PDMR Shareholding
17th Jul 20197:02 amRNSChange to Executive Committee
1st Jul 201912:40 pmRNSBlock listing Interim Review
1st Jul 201912:38 pmRNSTotal Voting Rights
1st Jul 201912:00 pmRNSDirector/PDMR Shareholding
10th Jun 201911:30 amRNSAnnual Financial Report
5th Jun 20199:52 amRNSHolding(s) in Company
5th Jun 20199:34 amRNSDirector/PDMR Shareholding
3rd Jun 201910:42 amRNSTotal Voting Rights
29th May 20194:00 pmRNSDirector/PDMR Shareholding
28th May 20194:12 pmRNSDirector/PDMR Shareholding
23rd May 20197:00 amRNSFinal Results
9th May 201911:00 amRNSDirectorate Change
1st May 201910:00 amRNSTotal Voting Rights
1st Apr 20194:17 pmBUSTotal Voting Rights
1st Apr 20193:45 pmBUSHolding(s) in Company
1st Mar 201911:21 amBUSTotal Voting Rights
27th Feb 20191:00 pmBUSHolding(s) in Company
7th Feb 20197:00 amBUSTrading Statement
1st Feb 201911:40 amBUSTotal Voting Rights
3rd Jan 20192:00 pmBUSDirector/PDMR Shareholding
2nd Jan 20193:53 pmBUSBlock listing Interim Review
6th Dec 201811:32 amBUSDirector/PDMR Shareholding
5th Dec 20182:22 pmBUSDirector/PDMR Shareholding
3rd Dec 20183:34 pmBUSTotal Voting Rights
19th Nov 20187:00 amBUSDirectorate change
8th Nov 20187:00 amBUSHalf-year Report
1st Nov 201812:20 pmBUSTotal Voting Rights
5th Oct 20182:05 pmBUSDirector/PDMR Shareholding
1st Oct 20182:25 pmBUSTotal Voting Rights
21st Sep 201811:43 amBUSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.